Vol. 2 No. 8 (2022)
Reimbursement Recommendations

Asciminib (Scemblix)

Published August 23, 2022

Key Messages

  • CADTH recommends that Scemblix should be reimbursed by public drug plans for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) if certain conditions are met.
  • Scemblix should only be covered to treat adults with Ph+ CML who are in chronic phase (CP) with treatment failure on or intolerance to 2 or more prior tyrosine kinase inhibitor (TKI) therapies and have no evidence of T315I or V299L
  • Scemblix should only be reimbursed if prescribed by clinicians with expertise and experience in treating CML and if the cost of Scemblix is reduced.